{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:05Z","timestamp":1784613905506,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prurigo nodularis (PN) is a chronic neuroimmune skin disorder characterized by intensely pruritic nodules, severe impairment of quality of life and significant psychosocial burden. Prior to the approval of targeted therapies, management relied on conventional agents with limited efficacy. Recent evidence of its neuroimmune pathogenesis have led to the approvement of targeted biologics. Dupilumab, a human monoclonal antibody targeting IL-4\/IL-13-axis, has been the first targeted therapy approved for PN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 75-year-old woman presenting with severe, treatment-na\u00efve generalized pruritus (IGA PN-S 4; NRS 9\/10; DLQI 21) with extensive nodular involvement of the trunk and extremities, complete sleep deprivation and important anxiety and depression (HADS.A 12; HADS-D 11). Following diagnosis of PN, treatment with dupilumab (600\u00a0mg loading dose, then 300\u00a0mg every 2\u00a0weeks) was initiated in October 2025. At approximately 6 weeks, marked pruritus reduction (NRS 3) and sleep restoration were observed. Progressive improvement continued over time. At 4 months follow-up, complete remission was nearly achieved (NRS 1, IGA PN-S 1, DLQI 2, HADS-A 4, HADS-D 3), with no adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case corroborates and extends the existing evidence on dupilumab efficacy in the treatment of moderate-to-severe PN, with particularly rapid and comprehensive responses across pruritus, skin lesions, sleep and psychosocial outcomes in an elderly patient, through IL-4\/IL-13 inhibition. Our findings support dupilumab as a safe and effective targeted option for severe PN, also in older patients where conventional systemic therapies, such as corticosteroids or immunosuppressants, carry a high risk of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1876166","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:20Z","timestamp":1784612120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe non-atopic prurigo nodularis in an otherwise healthy elderly patient: rapid multidimensional response to dupilumab"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandra","family":"Ventre","sequence":"first","affiliation":[{"name":"Allergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Nuccio","sequence":"additional","affiliation":[{"name":"Allergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[{"name":"Allergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ricciardi","sequence":"additional","affiliation":[{"name":"Allergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00403-025-03847-2","article-title":"Distinct comorbidity profiles in atopic versus non-atopic prurigo nodularis: a cross-sectional analysis","volume":"317","author":"Bao","year":"2025","journal-title":"Arch. Dermatol Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/medicina61040631","article-title":"New and emerging biologics and jak inhibitors for the treatment of prurigo nodularis: a narrative review","volume":"61","author":"Bianco","year":"2025","journal-title":"Medicina"},{"key":"B5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/1744666X.2023.2268291","article-title":"A critical review of dupilumab for adult patients with prurigo nodularis","volume":"20","author":"Biazus Soares","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1092685","DOI":"10.3389\/fimmu.2023.1092685","article-title":"Dupilumab for the treatment of prurigo nodularis: a systematic review","volume":"14","author":"Cao","year":"2023","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.abd.2023.11.003","article-title":"Prurigo: review of its pathogenesis, diagnosis, and treatment","volume":"99","author":"Criado","year":"2024","journal-title":"An. Bras. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13201","DOI":"10.1111\/dth.13201","article-title":"Efficacy of dupilumab in prurigo nodularis in elderly patient","volume":"33","author":"Giura","year":"2020","journal-title":"Dermatol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J. Investigative Dermatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40257-025-00993-1","article-title":"Efficacy and safety of dupilumab in adults with prurigo nodularis with or without atopic comorbidities: a subgroup analysis from two randomized phase III clinical trials","volume":"27","author":"Kim","year":"2026","journal-title":"Am. J. Clin. Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamadermatol.2021.5307","article-title":"Prurigo nodularis","volume":"158","author":"Kwatra","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br. J. Dermatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"adv00754","DOI":"10.2340\/actadv.v102.2151","article-title":"Dupilumab significantly reduces symptoms of prurigo nodularis and depression: a case series","volume":"102","author":"L\u00f6nndahl","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/jcm13030878","article-title":"Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84 weeks","volume":"13","author":"Paganini","year":"2024","journal-title":"JCM"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"501210","DOI":"10.1016\/j.abd.2025.501210","article-title":"Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials","volume":"100","author":"Vieira","year":"2025","journal-title":"An. Bras. Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.03.025","article-title":"Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)","volume":"16","author":"Yosipovitch","year":"2024","journal-title":"JAAD Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.5114\/ada.2025.152080","article-title":"Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients","volume":"42","author":"Zhao","year":"","journal-title":"Pdia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/all.16478","article-title":"Effectiveness and safety of dupilumab for prurigo nodularis in China: a multicentric and observational study","volume":"80","author":"Zhao","year":"","journal-title":"Allergy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1876166\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:21Z","timestamp":1784612121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1876166\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":22,"alternative-id":["10.3389\/fphar.2026.1876166"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1876166","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1876166"}}